REGENXBIO Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
REGENXBIO Inc. (RGNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-05
- REGENXBIO Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-03-31 was 1.60%.
- REGENXBIO Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 2.10%, a 19.23% decline year-over-year.
- REGENXBIO Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2014-09-30 was 2.60%.
- REGENXBIO Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.30%, a 7.50% increase from fiscal 2024.
- REGENXBIO Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.00%, a 2.56% increase from fiscal 2023.
- REGENXBIO Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.90%, a 129.41% increase from fiscal 2022.
- REGENXBIO Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.70%, a 183.33% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 4.30% 10-K · filed 2026-03-05 | ||||
| 2024-12-31 | 4.00% 10-K · filed 2026-03-05 | ||||
| 2023-12-31 | 3.90% 10-K · filed 2025-03-13 | ||||
| 2022-12-31 | 1.70% 10-K · filed 2025-03-13 | ||||
| 2021-12-31 | 0.60% 10-K · filed 2024-02-27 | ||||
| 2020-12-31 | 1.40% 10-K · filed 2023-02-28 | ||||
| 2019-12-31 | 2.30% 10-K · filed 2022-03-01 | ||||
| 2018-12-31 | 2.60% 10-K · filed 2021-03-01 | ||||
| 2017-12-31 | 2.10% 10-K · filed 2020-02-26 | ||||
| 2016-12-31 | 1.50% 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | 1.50% 10-Q · filed 2016-11-09 | ||||
| 2016-06-30 | 1.50% 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | 1.60% 10-Q · filed 2016-05-05 | ||||
| 2015-12-31 | 1.70% 10-K · filed 2016-03-03 | ||||
| 2015-09-30 | 2.10% 10-Q · filed 2015-11-05 | 1.70% 10-Q · filed 2016-11-09 | 2.10% 10-Q · filed 2015-11-05 | ||
| 2015-06-30 | 1.70% 10-Q · filed 2016-08-09 | ||||
| 2014-12-31 | 2.00% 10-K · filed 2016-03-03 | ||||
| 2014-09-30 | 2.60% 10-Q · filed 2015-11-05 | 2.60% 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |